High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection.
[BACKGROUND] Postoperative regimen selection between mFOLFIRINOX and GnP for recurrent pancreatic ductal adenocarcinoma (PDAC) lacks evidence, highlighting the need for a simple biomarker.
- p-value p = 0.024
- p-value p = 0.013
APA
Matsumoto T, Liu Z, et al. (2026). High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection.. Journal of hepato-biliary-pancreatic sciences, 33(2), 129-140. https://doi.org/10.1002/jhbp.70032
MLA
Matsumoto T, et al.. "High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection.." Journal of hepato-biliary-pancreatic sciences, vol. 33, no. 2, 2026, pp. 129-140.
PMID
41287981
Abstract
[BACKGROUND] Postoperative regimen selection between mFOLFIRINOX and GnP for recurrent pancreatic ductal adenocarcinoma (PDAC) lacks evidence, highlighting the need for a simple biomarker. This study explores the impact of γ-H2AX overexpression, a DNA damage marker, in resected PDAC for predicting platinum-based treatment response in recurrences.
[METHODS] In this study, we assessed γ-H2AX and ABCB1 expressions in resected PDAC tissues from 198 patients to evaluate their impact on prognosis after surgery and response to chemotherapy in 109 recurrent cases.
[RESULTS] High γ-H2AX expression was linked to shorter recurrence-free survival and overall survival (OS) compared to low expression (p = 0.024 and 0.0013). It was an independent poor prognostic factor post-surgery. In recurrent cases with high γ-H2AX expression, mFOLFIRINOX significantly improved OS compared to GnP (p = 0.013), while low γ-H2AX cases showed no significant OS difference between regimens (p = 0.576).
[CONCLUSIONS] γ-H2AX overexpression in PDAC tissue is an independent negative prognostic factor. In recurrent cases, high γ-H2AX expression suggests better OS and treatment response with mFOLFIRINOX, indicating its potential as a chemosensitivity marker for personalized therapy in PDAC recurrence.
[METHODS] In this study, we assessed γ-H2AX and ABCB1 expressions in resected PDAC tissues from 198 patients to evaluate their impact on prognosis after surgery and response to chemotherapy in 109 recurrent cases.
[RESULTS] High γ-H2AX expression was linked to shorter recurrence-free survival and overall survival (OS) compared to low expression (p = 0.024 and 0.0013). It was an independent poor prognostic factor post-surgery. In recurrent cases with high γ-H2AX expression, mFOLFIRINOX significantly improved OS compared to GnP (p = 0.013), while low γ-H2AX cases showed no significant OS difference between regimens (p = 0.576).
[CONCLUSIONS] γ-H2AX overexpression in PDAC tissue is an independent negative prognostic factor. In recurrent cases, high γ-H2AX expression suggests better OS and treatment response with mFOLFIRINOX, indicating its potential as a chemosensitivity marker for personalized therapy in PDAC recurrence.
MeSH Terms
Humans; Male; Female; Middle Aged; Pancreatic Neoplasms; Neoplasm Recurrence, Local; Aged; Histones; Carcinoma, Pancreatic Ductal; Antineoplastic Combined Chemotherapy Protocols; Prognosis; Biomarkers, Tumor; Irinotecan; Oxaliplatin; Retrospective Studies; Fluorouracil; Leucovorin; Adult; Pancreatectomy; Treatment Outcome
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.
- Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.
- A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis.
- Percutaneous aspiration and sclerotherapy for simple hepatic cysts: a systematic review and meta-analysis.
- A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol.